A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jeismar Carballo, PhD
- Phone Number: +34643794364
- Email: jcwo@jacintoconvit.org
Study Contact Backup
- Name: Isaac Blanca, Phd
- Phone Number: +582122355122
- Email: jefaturadeinvestigacion@jacintoconvit.org
Study Locations
-
-
Florida
-
Pompano Beach, Florida, United States, 33069
- Jacinto Convit World Organization, Inc.
-
Contact:
- Jeismar Carballo, PhD
- Phone Number: 954-970-9176
- Email: jcwo@jacintoconvit.org
-
-
-
-
Distrito Capital
-
Caracas, Distrito Capital, Venezuela, 1010
- Instituto de Oncología Dr. Luis Razetti
-
-
Miranda
-
Caracas, Miranda, Venezuela, 1071
- Fundación Jacinto Convit
-
Contact:
- Isaac Blanca, Phd
- Phone Number: +582122355122
- Email: jefaturadeinvestigacion@jacintoconvit.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female patients who are ≥18 years of age at the time of signing the informed consent forms (ICFs).
- Histologically- or cytologically-confirmed diagnosis of adenocarcinoma of the breast.
- Female patients with evidence of either locally advanced (not amenable to radiation therapy or surgery in a curative intent), inoperable, and/or metastatic disease who have either progressed, recurred after standard of care treatment, have refused, or are otherwise ineligible for standard of care treatment.
- Measurable disease with bidimensional measurements of at least 1 × 1 cm.
- Patients with a ≤10 mm diameter PPD response of skin induration.
- For patients who consent to paired biopsies (before treatment and during treatment): for baseline samples, a formalin-fixed and paraffin-embedded (FFPE) archived biopsy sample can be used, but fresh biopsies from primary or recurrence or metastasis are preferred.
- Female patients must not be pregnant, breastfeeding, nor be planning a pregnancy during their participation in the study. The use of an effective contraceptive method is mandatory in patients capable of having children. It is known that avoiding sexual activity (true abstinence) is the only secure method to prevent pregnancy; however, when patients choose to be sexually active, the participant must agree to use an appropriate "double-barrier" contraceptive method (such as the use of a diaphragm, intrauterine device [IUD], or contraceptive sponge, as well as the use of condom) or pills, injections or implants prescribed for birth control.
- Ability to understand and willingness to sign written ICFs.
Exclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥1.
- Life expectancy <3 months.
- Patients with known brain metastases, leptomeningeal carcinomatosis, and/or spinal cord compression. Participants with brain metastases that have been previously totally resected or irradiated are eligible provided no progression or relapse is observed within 4-weeks of the last treatment.
- Non-resolution of any prior treatment-related toxicity to Grade <2, except for alopecia according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
- Major surgery within 4-weeks before first study treatment administration.
- Washout period of at least 3-weeks or 5 times the half-life, whichever is shorter, of any cancer therapy (including anticancer therapy, vaccination, or any investigational agent). For patients who received immunotherapy (including anti-programmed death-1 [anti-PD-1] therapy) a washout of at least a 4-week recovery period is required.
- Immunosuppressive corticosteroid doses (prednisone >7.5 mg daily orally [PO] or intravenously [IV], or equivalent) within 2-weeks before the first dose of ConvitVax and maintenance therapy with prednisolone >7.5 mg/day PO or equivalent during the study.
- Inadequate hematological function including neutrophils <1.5 × 109/L; hemoglobin ˂9 gr/dL, and platelet count <100 × 109/L.
- Inadequate liver function test with total bilirubin ˃1.5 × upper limit of normal (ULN), unless Gilbert's syndrome (in which case, total bilirubin ˃2.5 × ULN or alanine aminotransferase [ALT], aspartate aminotransferase [AST], or alkaline phosphatase [ALP] ˃2.5 × ULN in the absence of hepatic metastases). In the presence of hepatic metastases, total bilirubin ˂3 × ULN and ALT (or AST) ˂5 × ULN are acceptable. ALP ˂5 × ULN would be acceptable only if related to the presence of bone metastases, as judged by the investigator.
- Inadequate renal function with serum creatinine ≥1.5 × ULN or between 1.0 and 1.5 × ULN with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 as estimated using the abbreviated Modification of Diet in Renal Disease formula.
- Inadequate coagulation test: prothrombin time (PT) or international normalized ratio (INR) value ˃1.5 × ULN. Patients with anticoagulant therapy are excluded. Patients with low dose aspirin (˂100 mg) and prophylactic low dose heparin are allowed.
- Patients with any other cancer. However, adequately treated basal, squamous carcinoma of the skin or in situ cervical cancer, or any other cancer from which the patient has been disease free for >3 years are allowed.
- Patient is deemed unsuitable for participation, whatever the reason, as judged by the investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to the study procedures (e.g., unwilling and unable to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restriction).
- Known or suspected contraindication to BCG and/or formalin.
- History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or active hepatitis A, B (defined as either positive HBsAg or negative HBsAg with positive HBc antibody), or C (defined as a known positive hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay) infection.
- Patients positive for Covid-19 or those who had the disease within a month before their inclusion in the study.
- Patients with previous or current active autoimmune disease requiring immunosuppressive treatment (e.g., inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, polymyositis, dermatomyositis, insulin-dependent diabetes mellitus [IDDM] or infant- juvenile diabetes, vasculitis syndrome, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis or other rheumatic diseases or any other related medical disorder.)
- Active infection that requires the continuous use of antibiotic therapy.
- Current pregnancy or breastfeeding.
- Known or proven adverse reaction to vaccines, such as anaphylaxis or other severe reaction.
- Any prior organ transplant.
- Prior treatment with live, attenuated vaccines within 4-weeks before initiation of study intervention and during treatment.
- Patients who had a splenectomy.
- Patients with known or suspected congenital immunodeficiency.
- Current participation in another clinical trial.
- Individuals accommodated in an institution because of regulatory or legal order; prisoners or subjects who are legally institutionalized.
- Active infections, including unexplained fever (temperature >38.1°C), or antibiotics therapy within 1-week before enrollment.
- Presence of any significant and uncontrolled medical, psychiatric, chronic condition, or laboratory abnormalities that may denote a risk associated with the patient's participation in the study, or that may interfere with the interpretation of the results, as judged by the investigator.
- Previous enrollment in this study.
- The patient is on the staff (or relative thereof) directly involved in the conduct of the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ConvitVax
ConvitVax is a vaccine made of three components: autologous tumor cells homogenate obtained from 0.3 g of tumor tissue, 0.0625 mg of BCG D1331, and 0.02% of formalin. There is no dose escalation in this study. Four doses of 0.5 mL of ConvitVax will be applied via id injection with a 2-week interval between each dose. |
ConvitVax is a personalized vaccine designed to treat women with breast cancer.
The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Criteria for disease recurrence
Time Frame: 3 months
|
Recurrence of the disease established by the Response Evaluation Criteria in Solid Tumors (RECIST) guide will be followed.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antitumor effect
Time Frame: 48 days
|
Tumor size will be measured (in centimeters) using a computed tomography (CT) scan with contrast.
|
48 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Duarte C MA, Carballo O JM, De Gouveia YM, Garcia A, Ruiz D, Gledhill T, Gonzalez-Marcano E, Convit AF. Toxicity evaluation of ConvitVax breast cancer immunotherapy. Sci Rep. 2021 Jun 16;11(1):12669. doi: 10.1038/s41598-021-91995-6.
- Godoy-Calderon MJ, Salazar V, Gonzalez-Marcano E, Convit AF. Autologous tumor cells/bacillus Calmette-Guerin/formalin-based novel breast cancer vaccine induces an immune antitumor response. Oncotarget. 2018 Apr 17;9(29):20222-20238. doi: 10.18632/oncotarget.25044. eCollection 2018 Apr 17.
- Godoy-Calderon MJ, Gonzalez-Marcano E, Carballo J, Convit AF. Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. Oncotarget. 2019 Nov 12;10(61):6546-6560. doi: 10.18632/oncotarget.27283. eCollection 2019 Nov 12.
- Convit J, Montesinos H, Oviedo H, Romero G, Maccarone B, Essenfeld E, Convit A, Palacios LE. Autologous tumor lysate/Bacillus Calmette-Guerin immunotherapy as an adjuvant to conventional breast cancer therapy. Clin Transl Oncol. 2015 Nov;17(11):884-7. doi: 10.1007/s12094-015-1320-0. Epub 2015 Jun 16. Erratum In: Clin Transl Oncol. 2016 Jun;18(6):650.
- Convit J, Pinardi ME, Rodriguez Ochoa G, Ulrich M, Avila JL, Goihman M. Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria. Clin Exp Immunol. 1974 Jun;17(2):261-5.
- Convit J, Aranzazu N, Pinardi M, Ulrich M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol. 1979 May;36(2):214-20.
- Convit J, and Ulrich M. Desarrollo de una autovacuna + BCG y su posible uso en el tratamiento del cáncer. Gaceta Médica Caracas. 2006; 114, 300-304.
- Convit, J. Inmunidad celular y su importancia en el cáncer de la mama. Gaceta Médica Caracas. 2008; 116, 248-249.
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JCWO-ConvitVax1b2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.